Product How it works Pricing Blog FAQ About Contact
Nektar Therapeutics

Nektar Therapeutics (NASDAQ: NKTR) revenue

Nektar Therapeutics reported revenue of $55.2m for fiscal 2025, 43.9% less than in fiscal 2024 ($98.4m). Since fiscal 2016 its revenue has fallen by 66.6%, an average decline of 11.5% a year.

Nektar Therapeutics's best year of the last 10 was fiscal 2018. The biggest drop was in fiscal 2019, −90.4%.

Revenue, in millions of US dollars165.42016307.720171,1932018114.62019152.92020101.9202192.1202290.1202398.4202455.22025
Embed this chart

Copy this code into your website or blog. The chart updates with each new annual report.

Revenue by fiscal year

Fiscal yearRevenueChangeOperating profitOperating margin
2025$55.2m−43.9%−$140.1m−253.7%
2024$98.4m+9.2%−$105.2m−106.9%
2023$90.1m−2.1%−$263.7m−292.6%
2022$92.1m−9.7%−$376.2m−408.6%
2021$101.9m−33.4%−$446.1m−437.8%
2020$152.9m+33.4%−$425.1m−278.0%
2019$114.6m−90.4%−$440.0m−383.9%
2018$1,193m+287.8%$687.9m57.6%
2017$307.7m+86.0%−$59.6m−19.4%
2016$165.4m—−$112.9m−68.2%

The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.

Nektar Therapeutics revenue compared with its sector

By revenue for its latest fiscal year, Nektar Therapeutics ranks 323rd of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Nektar Therapeutics, −43.9%.

RankCompanyRevenueRevenue growth
321stCVRX$56.7m10.4%
322nd908 Devices$56.2m17.7%
323rdNektar Therapeutics$55.2m−43.9%
324thAgios Pharmaceuticals$54.0m48.0%
325thInvivyd$53.4m110.5%

Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.

Questions about the revenue of Nektar Therapeutics

How much revenue did Nektar Therapeutics make in fiscal 2025?
Nektar Therapeutics reported revenue of $55.2m for fiscal 2025, compared with $98.4m in fiscal 2024.
How much has the revenue of Nektar Therapeutics fallen?
Between fiscal 2016 and fiscal 2025 it went from $165.4m to $55.2m: 66.6% less, an average decline of 11.5% a year.
What was the best year for revenue at Nektar Therapeutics?
Of its last 10 fiscal years, fiscal 2018, with $1,193m.
Where does Nektar Therapeutics rank in its sector by revenue?
It ranks 323rd of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
Where do the figures for Nektar Therapeutics come from?
From the annual report (Form 10-K) that Nektar Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.

Where each figure comes from

From the annual report (Form 10-K) that Nektar Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Nektar Therapeutics: the Nektar Therapeutics page · annual accounts · net income · insider transactions.

Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.